Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Immunogeniciteit en reactogeniciteit van heterologe ChAdOx1 nCoV-19/mRNA-vaccinatie
dec 2021 | Vaccinatie, Virale infecties